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Objectives: To assess the diagnostic potential of bidirectional axial transmission
(BDAT) ultrasound, and high-resolution peripheral quantitative computed tomography
(HR-pQCT) in X-linked hypophosphatemia (XLH, OMIM #307800), a rare genetic disorder
of phosphate metabolism caused by mutations in the PHEX gene.
Methods: BDAT bone ultrasoundwas performed at the non-dominant distal radius (33%
relative to distal head) and the central left tibia (50%) in eight XLH patients aged between
4.2 and 20.8 years and compared to twenty-nine healthy controls aged between 5.8
and 22.4 years. In eighteen controls, only radius measurements were performed. Four
patients and four controls opted to participate in HR-pQCT scanning of the ultradistal
radius and tibia.
Results: Bone ultrasound was feasible in patients and controls as young as 4 years
of age. The velocity of the first arriving signal (νFAS) in BDAT ultrasound was significantly
lower in XLH patients compared to healthy controls: In the radius, mean νFAS of XLH
patients and controls was 3599 ± 106 and 3866 ± 142 m/s, respectively (−6.9%;
p < 0.001). In the tibia, it was 3578 ± 129 and 3762 ± 124 m/s, respectively (−4.9%;
p = 0.006). HR-pQCT showed a higher trabecular thickness in the tibia of XLH patients
(+16.7%; p = 0.021).
Conclusions: Quantitative bone ultrasound revealed significant differences in cortical
bone quality of young XLH patients as compared to controls. Regular monitoring of XLH
patients by a radiation-free technology such as BDAT might provide valuable information
on bone quality and contribute to the optimization of treatment. Further studies are
needed to establish this affordable and time efficient method in the XLH patients.
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INTRODUCTION
X-linked hypophosphatemia (XLH, OMIM #307800) is a
rare disorder of phosphate homeostasis with an estimated
prevalence of 8–17 per million (1). Caused by a loss-of-function
mutation in the PHEX (phosphate regulating endopeptidase
homolog, X-linked) gene, upregulation of FGF23 expression
leads to an inhibition of renal phosphate reabsorption and
results in low serum phosphate levels and impaired 1-alpha-
hydroxylase activity (2, 3). Despite x-chromosomal inheritance
and heterozygosity in females, penetrance is reported to be 100%
by 1 year of age in both sexes (4).
Key symptoms of the profound chronic hypophosphatemia
are progressive bone deformities, which mostly occur at the age
of weight bearing. Further, impaired longitudinal growth and
disproportionate short stature impair quality of life in adult age
(5, 6). In childhood, radiographic signs of rickets manifest as
widening of the growth plates and metaphyseal flaring (7). Extra-
skeletal ossifications in ligaments or at ligament attachment sites,
called enthesopathies, may occur in later adulthood. Endodontic
problems such as root infections and early loss of teeth are
common among the XLH population (6). Different forms of
hypophosphatemic rickets are often associated with muscle
weakness, which is usually mild in XLH patients (8, 9). However,
radiologic presentation and clinical phenotype are extremely
variable and do not seem to be linked with genotype (10, 11).
Dysregulation of matrix regulation and impaired mechanical
resistance due to chronic hypophosphatemia are causative for
the long-term development of mobility impairing deformities
of the lower extremity. Thus, skeletal imaging in pediatric XLH
patients for the evaluation of the affection of the mineralizing
matrix is highly valuable for initial work-up, monitoring of
treatment as well as evaluation of surgical options. Clinical
imaging is mostly based on radiographs and rickets severity
scoring (RSS) as described and validated by Thacher et al.
(12, 13). Due to the lack of quantitative tools, standardized but
subjective RSS rating is considered as gold-standard for rachitic
affection of bone. While this observer-dependent scoring of the
affection of growth plates and adjacent mineralizing tissue has
been validated in XLH Patients (13), surgical interventions are
mostly performed in diaphyseal bone which is not rated by
RSS. Surgical planning for the correction of limb deformities,
axial deviations, or length calculations is commonly assessed
by cross-sectional imaging such as computed tomography (CT)
or magnetic resonance imaging (MRI). With these imaging
modalities the mineralization phenotype can only be assessed
indirectly bymeans of growth-plate abnormalities or deformities.
Therefore, complementary information about tissue properties
would be valuable in pre-surgery assessment in rachitic disorders
such as XLH.
In XLH patients, dual-energy x-ray absorptiometry (DXA)
studies have shown a tendency of higher mineralization in the
axial skeleton and lower mineralization in the appendicular
skeleton (6, 7, 14, 15). As a two-dimensional measurement
of a three-dimensional structure, DXA only reflects areal
bone mineral density (aBMD) (7). Moreover, DXA does
not provide information on bone microarchitecture and
compartment-specific BMD. In aBMD, a size artifact arises,
where small bones seem to have lower BMD and large bones
higher BMD. Considering the growth disturbances in XLH, DXA
results have to be interpreted with caution (16). To account
for this size artifact, Carter et al. proposed a calculation of
bone mineral apparent density (BMAD) to estimate volumetric
BMD (vBMD) (7, 17). BMAD can be calculated by mathematical
equations using DXA aBMD results (7). Beck-Nielsen et al.
reported that children and adults with XLH have elevated BMAD
of the lumbar spine (7). However, Colares Neto et al. examined
37 children and adults with XLH stratified by age group and
reported that mean aBMD was only elevated in adults (16).
DXA interpretation in XLH patients remains complex and results
may not accurately portray bone mineralization (7, 16). Factors
such as anthropometric data or presence of enthesopathies can
influence aBMD (6, 7).
High-resolution peripheral quantitative computed
tomography (HR-pQCT) can be used to assess bone geometry,
bone microarchitecture, and compartment-specific volumetric
bone mineral density (vBMD) at the distal radius and the distal
tibia (18). Until now, the literature on HR-pQCT in patients
with XLH remains limited (16, 19). Colares Neto et al. examined
bone mineral density and microarchitecture by HR-pQCT and
found that XLH patients had lower trabecular vBMD and thus
lower total vBMD, especially at the load-bearing distal tibia.
The trabecular microarchitecture was significantly different in
both the radius and the tibia with XLH patients having lower
trabecular number, more trabecular separation, and higher
trabecular network inhomogeneity (16). Shanbhogue et al.
reported similar changes in trabecular microarchitecture (19).
Quantitative ultrasound (QUS) is increasingly being used
to assess bone status beyond BMD (20, 21). Apart from its
cost-effectiveness and convenience, a radiation-free method
of bone assessment is desirable, especially in children. Most
of the current QUS technologies focus on the measurement
of cortical bone at radius, tibia, or phalanges, either in axial,
or in through-transmission modes. Various applications of
QUS in children are summarized in (22). These and other
studies conducted in adults confirm that parameters derived
from QUS measurements provide information that is, at
least in part, independent of BMD. However, for many QUS
modalities the associations between the derived parameters
and bone properties are only poorly understood. During the
last decade, much effort has been dedicated to the so-called
bi-directional axial transmission (BDAT) modality. The bi-
directional measurement corrects for probe inclination due to
variable soft-tissue thickness. The velocity of the first-arriving
signal (hereinafter simply called νFAS) is directly linked to
cortical tissue stiffness, cortical porosity (Ct.Po), and cortical
thickness (Ct.Th) (23). It should be noted that the thickness
dependence is related to the ratio of the acoustic wavelength
to thickness, i.e., for low frequencies and thin cortical bone,
the latter has a dominant effect on variations of νFAS, whereas
for higher frequencies and thicker cortical bone, νFAS becomes
independent of Ct.Th variations. The most recent system uses
this relationship by means of a spatiotemporal spectral analysis
and some assumptions, such as a constant tissue stiffness, to
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obtain Ct.Th and Ct.Po at the radius and tibia of adult humans
(24, 25).
This pilot study is the first to examine BDAT ultrasound in
patients with XLH. The νFAS parameter was used as a marker
for variations in cortical bone properties. As it is known that
XLH leads tomineralization defects withmany hypo-mineralized
holes in the cortical tissue matrix, increased pore size, and
higher porosity (26), we hypothesized that the combined effect
of compromised tissue mineralization and increased porosity in
XLH patients results in decreased compressional wave velocities,
as measured by means of νFAS at 1 MHz. Secondary aims were to
assess microarchitectural changes of trabecular and cortical bone
by HR-pQCT in patients with XLH.
MATERIALS AND METHODS
Subjects
This study was approved by the ethics committee of the Medical
University of Vienna (Vote 2201/2015). We obtained written
informed consent from all participants (or their guardians,
depending on participant age), and assent from children above
the age of 14 years.
Children above the age of four, adolescents, and young adults
were included in this study. Diagnosis of XLH was confirmed in
all patients either by genetic analysis or by biochemical testing
in genetically verified familial cases. All patients were diagnosed
and treated within the first 2 years of life (Table 1). Patient
compliance was considered as sufficient in 7/8 patients by the
treating physician. All XLH patients had blood draws as part
of routine care. Serum calcium, serum phosphate, parathyroid
hormone (PTH), vitamin D [25-(OH)D], calcitriol [1,25-
(OH)2D], and alkaline phosphatase activity (ALP) were analyzed.
In addition, urinary parameters such as calcium/creatinine ratio
and the ratio of tubular maximum reabsorption of phosphate
to glomerular filtration rate (TmP/GFR) were measured in
XLH patients.
As control group, healthy children, adolescents, and young
adults (n = 4) were recruited from the Division of Pediatric
Surgery, Department of Surgery, Medical University of Vienna.
Additional QUS control data were available from volunteers
measured at Charité-Universitätsmedizin Berlin (n = 26). In
total, QUS data from 37 subjects (i.e., 8 XLH patients, 3 controls,
data from 26 healthy volunteers) were included in this study. HR-
pQCT scanning of the ultradistal radius and tibia was performed
in four patients and four controls.
Exclusion criteria for the control group were chronic diseases
that affect themotion apparatus, increased likelihood of fractures,
bone deformities, chronic inflammatory diseases, malabsorption,
metabolic diseases, or diseases of the muscle. Additional
exclusion criteria for both the XLH and the control group
included bilateral lower leg or forearm fractures, and pregnancy.
Quantitative Ultrasound (QUS)
Ultrasound measurements were performed using a prototype
system (BDAT Ultrasonic Module, serial number 001, software
version 3.1, CETU Althaïs Technologies, Tours, France), as
described in (27). Briefly, the system consists of a custom array
transducer (Figure 1) with 2 × 5 transmitter elements on each
side and 24 central receiver elements (Vermon, Tours, France).
The transmit elements are subsequently excited with short
positive signals, which resulted in the emission of broadband
pulses of about 0.5–1.5 MHz. For each excitation, the transmitted
signals were recorded simultaneously with all receiver elements.
Each measurement cycle was repeated 100 times. During the
measurement the probe was slightly moved, to ensure the
acquisition under variable probe orientations relative to the bone.
The measurements were performed at the non-dominant distal
radius (33% relative to distal head) and the central left tibia
(50%). At the tibia the probe was centered at the medial side (M)
and at the radius, the probe was centered at the postero-lateral
side (Figure 2). In case of a local fracture or fracture history
of the non-dominant radius or left tibia, the contralateral side
was scanned. If a measurement of νFAS has been repeated, the
median of all measurements was calculated. For the evaluation of
QUS, additional control patients from Berlin have been included
in the data analysis. Note that in eighteen out of these twenty-
six controls, only measurements at the radius were made. As
a result, 8 children and adolescents with XLH (4–20 years old)
and 29 healthy age-matched controls (5–22 years old) have been
included. Independent of the recruitment site, all subjects were
measured with the same ultrasound device by two experienced
operators (KR and JS).
QUS Data Analysis
The estimation of the velocity of the first arriving signal
has been described in detail (28). The first signal arriving at
a receiver element can be a signal (i) propagating directly
from emitter to receiver through soft tissue with a velocity of
approximately 1540 m/s, (ii) coupled into cortical bone as a
non-dispersive compressional wave with a velocity > 3,500 m/s,
or (iii) coupled into the cortical shell as a dispersive guided
wave (Figure 1). We have developed an optimized automated
algorithm that recognizes receiver elements detecting wave
propagation only through soft tissue and excluded those from
subsequent νFAS calculation (Figure 3A). The velocity in one
propagation direction was determined from the linear slope
between arrival time and emitter-receiver distance (Figure 3B).
The harmonic mean of the velocities in both propagation
directions was calculated to compensate for variable soft-tissue
thickness along the propagation path. From the distribution of all
measured velocities, the one occurring with the highest frequency
(peak position) was used for further analysis (Figure 3C). The
inter-operator in-vivo precision for this measurement is in the
order of 0.5% (28).
HR-pQCT Imaging
To assess volumetric bone mineral density, bone geometry,
and bone microarchitecture of the ultra-distal extremities, we
used a clinical HR-pQCT system (XtremeCT I, Scanco Medical,
Brütisellen, Switzerland). The non-dominant ultradistal radius
and left ultradistal tibia were scanned. After an anteroposterior
scout projection, a reference line was placed at the physis or the
physis remnant. In XLH, the reference line was placed at the nadir
of the cupped physis. Cupping in skeletally immature children
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TABLE 1 | Descriptive statistics of XLH patients.
XLH patients (n = 8) Reference ranges
Basic clinical parameters Age (yr) 12.9 ± 5.8 [13.4]
Sex (f/m) 7/1
Body height (cm) 135.0 ± 23.3 [145.4]
Body height SDS −2.2 ± 1.1 [−2.0]
BMI SDS 0.58 ± 1.06 [0.99]
Body ratio (sitting height/leg length) SD 1.7 ± 1.3 [1.65]
Laboratory parameters Serum Ca (mmol/L) 2.3 ± 0.1 [2.3] 2–12 y: 2.2–2.7; 12–18 y: 2.1–2.55
Serum P (mmol/L) 0.88 ± 0.11 [0.9] 1–12 y: 1.0–2.3; > 12 y: 0.81–1.45
PTH (pg/mL) 51.48 ± 20.08 [48.2] 15–65 pg/ml
25D (nmol/L) 50.74 ± 22.60 [51.1] > 50 nmol/L
1,25D (pg/mL) 44.88 ± 18.19 [45] 19.9–79.3 pg/ml
ALP (U/L) 309.13 ± 174.40 [360] Age-specific according to (39)
Urinary parameters Ca/Crea ratio 0.20 ± 0.28 [0.115] < 0.70 mmol/mmol
TmP/GFR (mmol/L) 0.73 ± 0.08 [0.69] 1.15–2.44
Treatment Phosphat (mg/kg KG/d) 40.25 ± 15.16 [40.06]
Calcitriol (ng/kg KG/d) 19.47 ± 12.62 [21.13]
Treatment duration (y) 11.63 ± 5.3
Values are expressed as mean ± SD [median].
FIGURE 1 | Principle of bi-directional axial ultrasound transmission. The ultrasound transducer consists of two emitter arrays and one receiver array separated by gel
filled gap regions (dimensions are given in mm). The numerical sound propagation simulation shows an ultrasound pulse emitted at element 3 of emitter array 1, which
propagates through skin and soft tissue into the bone. One part of the wave is transmitted into the medullary canal and other parts propagate as compressional and
dispersive guided waves in the axial bone direction through the cortical shell. These waves leak acoustic waves back into the soft tissue which are detected by the
central receiver array.
with XLH was only mild in our patient cohort (Thacher Grade
1) (12). In between the reference line and the scan volume, we
used a fixed distance of 2mm. Each scan volume was 9mm long.
The standard in-vivo protocol as described in the literature used
the following settings: 60kVP, 900 µA, 100ms integration time
(18, 29). The matrix size was 1536 × 1536, and the nominal
resolution 82 µm.
In case of a local fracture or fracture history of the non-
dominant radius or left tibia, the contralateral side was imaged.
Scan time was ∼3min per site and the effective dose in radius
and tibia 3 µSv, respectively. If unacceptable motion occurred,
scans were repeated once.
Trabecular Bone Analysis
The standard evaluation software of Scanco Medical XtremeCT
has been used to evaluate trabecular parameters including
trabecular bone volume fraction (BV/TV), trabecular number
(Tb.N), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp),
and trabecular network inhomogeneity (Tb.1/N.SD). The
precisions for these parameter estimations have been reported in
the range between 1.0 and 4.4% (18).
Cortical Bone Analysis
For extended cortical analysis a method developed by Burghardt
et al. has been employed (30–32). Parameters evaluated were
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FIGURE 2 | Ultrasound measurement locations. The landmarks used for the
identification of the longitudinal positions are marked by red dots. (Adapted
from Servier Medical Art by Servier under a Creative Commons Attribution 3.0
Unported License).
cortical BMD (Ct.BMD), cortical thickness (Ct.Th), cortical pore
volume (Ct.PoV), cortical porosity (Ct.Po), mean pore diameter
(Po.Dm), and standard deviation of mean pore diameter
(Dm.SD). The precisions for the structural parameter estimations
have been reported to be in the range between 0.6 and 0.92% (30).
Statistical Analysis
IBM SPSS Version 24 was used for statistical analysis. Data
distribution was explored by inspection of histograms and
boxplots. A Lilliefors test was used to test if data were normally
distributed. Linear regression analysis and Pearson’s correlation
coefficients were used to assess the age dependency of νFAS. For
normally distributed values, mean and standard deviation were
calculated. For values with non-normal distribution, the median
and percentiles were calculated. An unpaired student’s t-test was
used to test for differences between XLH patients and controls.
Statistical significance was defined as p ≤ 0.05.
RESULTS
Subject Characteristics
In total, QUS data from 37 subjects were included in this study.
There was no significant difference in the mean age of XLH
patients and QUS controls (12.9 ± 5.8 vs. 15.9 ± 4.1 years;
p = 0.10). Sex ratio was 1:8 males in XLH patients compared to
5:29 male QUS controls. All XLH patients received conventional
treatment with phosphate and activated vitamin D since early
childhood. For detailed patient XLH characteristics see Table 1.
TheHR-pQCT controls were 9.9–22.8 years old (mean age 15.6±
4.7 years) and consisted of three females and one male. The XLH
patients that participated in HR-pQCT were 14.4 ± 3.5 years old
compared to 15.6 ± 4.7 years for controls. XLH patients differed
from the reference population regarding height (mean z-score
−2.2) according to Austrian reference values (33). Sitting height
to leg length ratio was higher than in the reference population
(mean z-score 1.7).
Quantitative Ultrasound (QUS)
In total, eight XLH patients and 29 controls participated in
the QUS assessment. All XLH patients and 11 controls were
measured at radius and tibia. From 18 controls, no tibia data were
available. The νFAS values were normally distributed. There was a
positive association of νFAS with age in the radius (R = 0.74, p
< 0.001), but not in the tibia (Figure 4). Significant differences
in νFAS between XLH patients and controls were observed in
both, radius and tibia: In the radius, mean νFAS of XLH patients
and controls was 3599 ± 106 and 3866 ± 142 m/s, respectively
(−6.9%; p< 0.001). In the tibia, it was 3578± 129 and 3762± 124
m/s, respectively (−4.9%; p= 0.006). As can be seen in Figure 4,
νFAS remained consistently lower in XLH patients across the age
range of our study population.
HR-pQCT
Four XLH patients and four controls opted to participate in
HR-pQCT scanning. Figure 5 shows HR-pQCT images of two
XLH patients and two controls in the axial and reconstructed
coronal plane. Mean values and standard deviations can be
found in Table 2. Trabecular thickness (Tb.Th) in the tibia
was significantly higher in XLH patients than in controls
(+16.7%; p = 0.021). In the radius, Tb.Th was also increased
in XLH patients, however not statistically significant (+33.3%;
p = 0.118). In both the radius and tibia, XLH patients
exhibited lower mean trabecular number (Tb.N), higher mean
trabecular spacing (Tb.Sp) and higher mean trabecular network
inhomogeneity (Tb.1/N.SD), though not statistically significant.
Cortical thickness (Ct.Th) in the tibia showed a tendency to be
higher in XLH patients than in controls (+18.8%; p = 0.061).
Paired data of patients undergoing both HR-pQCT and QUS can
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FIGURE 3 | Ultrasound signals recorded at the receiver array after the excitation of a signal from one emitter (A). For each receiver element, the first arriving signal
exceeding the noise floor (magenta) is time-gated (green) and the time-of-flight of the first peak (red crosses) is detected. Pulse travel times linearly increasing with
emitter-receiver distance are used to calculate the propagation velocity in this direction (B). Other signals [the encircled signal of receiver channel 1 in (A)], were
automatically excluded. From the distribution of all measured velocities, the peak position was used for further evaluation.
FIGURE 4 | Results of quantitative ultrasound at the radius (A) and the tibia (B).
be found in Figure S1. Because of the low number of paired data
(n= 7) no statistical analysis was performed.
DISCUSSION
The main finding of this study was that the velocity of the
first arriving signal (νFAS) measured by bi-directional axial
transmission (BDAT) bone ultrasound in the radius and tibia
is significantly lower in XLH patients compared to healthy
controls. This finding is in agreement with the hypothesis
that compromised cortical bone tissue properties in XLH
patients (i.e., lower tissue mineralization, hypo-mineralized
holes, increased pore size, higher porosity) result in a reduction
of the compressional wave velocities compared to age-matched
controls. The range of values and age dependency of the νFAS is in
agreement with reference values obtained by a comparable axial
transmission device (34).
Musculoskeletal symptoms associated with bone deformities
and skeletal muscle fatigue significantly contribute to the
burden of disease in children and adults with XLH: More
than 80% of children and adults report abnormal gait and
skeletal pain underlining the disease impact on quality of
life (5). On radiographs, typical imaging signs of rickets and
osteomalacia including poor fracture healing can be observed
(3, 35). Previously, DXA studies have shown increased aBMD
in adult XLH patients, especially in the axial skeleton (6, 7, 14–
16). Bearing in mind that DXA is a projectional technique of
low image resolution, which is further affected by anthropometric
indices, DXA is clearly unable to provide a full insight into bone
quality in XLH. Specifically, bone microarchitecture including
Ct.Po cannot be measured by DXA. Histological studies have
shown mineralization defects (14, 26), but necessitate an invasive
procedure. Bone quality can be assessed non-invasively by HR-
pQCT. Microarchitectural changes in both the cortical and
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FIGURE 5 | Representative axial and coronal HR-pQCT images of the ultradistal tibia of XLH patients (n = 2; A,B) compared to healthy controls (n = 2; C,D). Images
marked with the same letter belong to the same individual.
trabecular bone have been reported in HR-pQCT studies (16,
19). QUS represents another option for non-invasive assessment
of bone quality not involving ionizing radiation, which is an
advantage especially in children. To our best knowledge, no
studies have investigated QUS in XLH so far.
Previous studies showed impaired ultrasound properties
(e.g., sound velocity and attenuation) in children with growth
disturbances and bone disorders (22). The mineralization
defects of the tissue matrix in XLH patients are believed
to create a “vicious cycle”, i.e., softer tissue leads to more
strain, overstimulation of osteocytes, and increased formation
of deformed bone (26). This explains why XLH patients have
equal or even increased levels of BMD measured by DXA
or HR-pQCT compared to healthy subjects, despite softened
cortical bone, as measured by BDAT. All of our XLH study
patients underwent treatment at the time of the study, but
the compromised mechanical competence of the cortical bone
tissue in XLH patients was clearly visible both, in the clinical
phenotype and by means of reduced νFAS values in the tibia
and radius bones. νFAS is a surrogate measure of three cortical
bone properties contributing to bone stiffness and strength, i.e.,
Ct.Th, tissue matrix stiffness, and Ct.Po (23). For a thickness-
wavelength ratio smaller than 0.5, νFAS represents a guided
wave propagation mode, which is slower than the compressional
wave mode measured for larger thickness-wavelength ratios. For
our measurements, νFAS values can be considered to represent
the velocity of compressional waves. The absolute deviation of
individual values from age and gender-matched controls may be
a suitable indicator for the severity of the mineralization deficit.
However, the individual parameters contributing to the reduction
of νFAS in XLH patients remain subject to further studies,
which should also integrate more recent techniques that are able
to measure Ct.Th, Ct.Po, and speed of sound independently
(24, 36, 37) as well as second-generation HR-pQCT, which can
provide site-matched measurements at central shaft regions. As
BDAT and other ultrasound-based quantitative bone imaging
modalities use no ionizing radiation, they would be ideal for
the treatment monitoring of children and young adults with
bone diseases.
As the number of HR-pQCT sub-study participants was
very small, results have to be interpreted with caution. Also,
the scanning position is harder to be set in XLH patients
due to the different morphology of the physis compared to
healthy individuals. In concordance with Colares Neto et al. and
Shanbhogue et al. the children and adolescents with XLH in
our study exhibited lower trabecular number, higher trabecular
spacing and higher trabecular network inhomogeneity, though
not statistically significant. In the ultra-distal tibia, trabecular
thickness (Tb.Th) was significantly higher in XLH patients
compared to healthy controls (p = 0.021). Colares Neto et al.
have reported greater Tb.Th in the radius of XLH patients than in
controls and after stratification by age higher Tb.Th in children
than in adults. In contrast, they did not find any significant
differences in Tb.Th in the tibia (16). Shanbhogue et al. did
not find any significant differences in Tb.Th between adult XLH
patients and healthy controls in neither the radius nor the tibia
(19). Our predominantly young study population may explain
this finding.
Quantitative bone ultrasound may be a complementary tool
to monitor treatment response and optimize drug dosing.
Although axial transmission is not an imaging modality and
can therefore not provide information about the degree of bone
deformity or visualize the growth plate, it measures cortical
bone properties in long bones, which is not accessible with
conventional imaging modalities.
Treatment options for XLH are currently expanding beyond
phosphate and vitamin D. A novel treatment with burosumab,
a FGF-23 antibody, has shown superiority to conventional
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Ct.BMD (mg HA/cm3) 676 ± 105 651 ± 98 0.742 −3.7
Ct.Th (mm) 0.72 ± 0.10 0.74 ± 0.10 0.809 2.8
BV/TV 0.13 ± 0.03 0.15 ± 0.03 0.384 15.4
Tb.N (1/mm) 2.12 ± 0.45 1.98 ± 0.30 0.611 −6.6
Tb.Th (mm) 0.06 ± 0.01 0.08 ± 0.02 0.118 33.3
Tb.Sp (mm) 0.43 ± 0.12 0.44 ± 0.09 0.888 2.3
Tb.1/N.SD (mm) 0.17 ± 0.06 0.19 ± 0.06 0.607 11.8
Porosity
Ct.PoV (mm3) 1.36 ± 0.83 0.54 ± 0.34 0.115 −60.3
Ct.Po (%) 0.28 ± 0.17 0.17 ± 0.18 0.403 −33.3
Po.Dm (mm) 0.15 ± 0.03 0.14 ± 0.03 0.591 −6.7
Dm.SD (mm) 0.07 ± 0.03 0.06 ± 0.03 0.665 −14.3
ULTRADISTAL TIBIA
Basic HR-pQCT measures
Ct.BMD (mg HA/cm3) 651 ± 80 692 ± 79 0.499 6.2
Ct.Th (mm) 0.69 ± 0.10 0.82 ± 0.05 0.061 18.8
BV/TV 0.15 ± 0.02 0.13 ± 0.04 0.424 −13.3
Tb.N (1/mm) 2.33 ± 0.41 1.72 ± 0.60 0.147 −26.2
Tb.Th (mm) 0.06 ± 0.00 0.07 ± 0.00 0.021* 16.7
Tb.Sp (mm) 0.38 ± 0.08 0.59 ± 0.34 0.252 55.3
Tb.1/N.SD (mm) 0.15 ± 0.04 0.31 ± 0.25 0.245 106.7
Porosity
Ct.PoV (mm3) 4.10 ± 3.01 3.32 ± 4.87 0.793 −19.0
Ct.Po (%) 0.55 ± 0.32 0.38 ± 0.54 0.592 −33.3
Po.Dm (mm) 0.15 ± 0.01 0.18 ± 0.03 0.092 20.0
Dm.SD (mm) 0.06 ± 0.01 0.10 ± 0.05 0.174 66.7
Values are expressed as mean ± SD. Bold font* indicates a significant difference.
treatments regarding improvement of rickets and linear growth
(38). Future studies should look further into the pathomechanism
of νFAS reduction in XLH patients and how to use this
information for treatment monitoring—be it the traditional
phosphate and vitamin D approach or burosumab. The ultimate
goal would be to prevent skeletal deformities in XLH patients.
Quantitative bone ultrasound, in particular BDAT may also
represent a promising tool for radiation free monitoring of other
pediatric bone disorders with cortical phenotypes, including
primary, or secondary osteoporosis.
The main limitation of our study is a low sample size as a
result of the low prevalence of XLH.We lacked power to evaluate
associations between νFAS and structural parameter as well as sex
differences, because of the small number of subjects in this study.
On the other hand, strengths of our study are that it is the first
study to investigate QUS in XLH patients and healthy controls.
Another strength is the age range of our study participants, which
were predominantly pediatric, an age group that is most often
referred to clinicians in specialized treatment centers.
In conclusion, we could prove that νFAS measured using BDAT
ultrasound can be used as surrogate parameter for decreased
matrix stiffness and/or increased Ct.Po in XLH. Pediatric
and young adult patients with XLH exhibited a significant
reduction in νFAS as compared to healthy controls. BDAT
or other novel quantitative bone ultrasound modalities could
potentially be used for radiation-free treatment monitoring in
XLH to improve treatment guidance and to evaluate novel
therapeutic options.
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